MindImmune Therapeutics, Inc. Raises $10,200,000 Series A

MindImmune Therapeutics, Inc. has raised $10,200,000 in a funding round, securing investment capital from investors to advance its innovative work in neuro-inflammation. The pre-clinical stage company is focused on developing therapeutics for Alzheimer's disease (AD) as its initial clinical indication, aiming to address a significant unmet medical need. The company's lead program is an antibody-based therapeutic designed to inhibit an innate immune response originating in the periphery, which is believed to be triggered by AD pathology. This program is currently in late-stage pre-clinical development, with MindImmune contemplating an Investigational New Drug (IND) filing in the near future. Scientists at MindImmune are at the forefront of recognizing and leveraging the therapeutic opportunities in targeting the immune system to treat brain diseases, a strategy that could represent a fundamental breakthrough for the AD field if successful in clinical development. This newly secured capital will be instrumental in advancing MindImmune’s lead program towards clinical trials and supporting its planned IND filing. The funds will also contribute to the further development of its drug pipeline. Based in Kingston, RI, MindImmune is also building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island, a move that leverages the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to accelerate its drug development efforts. The successful funding round positions MindImmune Therapeutics to continue its critical research and development, progressing its mission to bring a novel therapeutic strategy to patients suffering from Alzheimer's disease. The company looks forward to leveraging this investment to drive its innovative programs and achieve key developmental milestones in the coming period.